Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Teva Pharm CEO calls for faster US generic drug approvals
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
Teva Pharm CEO calls on Trump for faster US drug approvals
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
FiercePharma12d
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...